Alnylam Pharmaceuticals | ALNY - Gross Profit On Sales

Stock Price
328.14
Daily Change
-3.10 -0.94%
Monthly
-22.33%
Yearly
18.81%
Q1 Forecast
327.65

Alnylam Pharmaceuticals reported $1.05B in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 256.99M 13.15M Sep/2025
Agios Pharmaceuticals USD 11.2M 448K Sep/2025
Alnylam Pharmaceuticals USD 1.05B 418.14M Sep/2025
Amgen USD 6.48B 307M Sep/2025
Arrowhead Research USD 256.47M 228.7M Sep/2025
BioMarin Pharmaceutical USD 631.2M 39.27M Sep/2025
Incyte USD 1.27B 130.22M Sep/2025
Ionis Pharmaceuticals USD 155M 293M Sep/2025
Moderna USD 809M 791M Sep/2025
Neurocrine Biosciences USD 780.9M 104.7M Sep/2025
Novartis USD 10.82B 694M Sep/2025
PTC Therapeutics USD 187.69M 24.3M Sep/2025
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Sanofi EUR 8.45B 3.02B Dec/2025
Sarepta Therapeutics USD 247.9M 209.96M Sep/2025
Takeda JPY 790.55B 262.97B Dec/2025
Tectonic Therapeutic USD 0 0 Mar/2025
Ultragenyx Pharmaceutical USD 131.94M 11.55M Sep/2025
Vertex Pharmaceuticals USD 2.66B 104.4M Sep/2025
Xencor USD 21M 22.61M Sep/2025